Satraplatin demonstrates clinical benefit in patients with advanced hormone-refractory prostate cancer: Results of the global phase III satraplatin and prednisone against refractory cancer (sparc) trial

被引：0
|
作者：
Sartor, O.
Petrylak, D.
Witjes, F.
Berry, W.
Chatta, G.
Vaughn, D.
Sternberg, C. N.
机构：
来源：
CANCER INVESTIGATION | 2007年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：19 / 20
页数：2
相关论文
共 50 条
  • [21] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience
    Cicero, G.
    De Luca, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (03) : 325 - 331
  • [23] Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
    Sartor, O
    Weinberger, M
    Moore, A
    Li, AL
    Figg, WD
    UROLOGY, 1998, 52 (02) : 252 - 256
  • [24] Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial
    Sternberg, C. N.
    Petrylak, D.
    Witjes, F.
    Ferrero, J.
    Eymard, J.
    Falcon, S.
    Chatta, K.
    Vaughn, D.
    Berry, W.
    Sartor, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Weekly docetaxel for advanced hormone-refractory prostate cancer
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V.
    Leonardi, V.
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : VII154 - VII154
  • [26] Chemotherapy for patients with hormone-refractory prostate cancer
    Joly, F
    Tannock, IF
    ANNALS OF ONCOLOGY, 2004, 15 (11) : 1582 - 1584
  • [27] Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer
    Kolodziej, Michael
    Neubauer, Marcus A.
    Rousey, Steven R.
    Pluenneke, Robert E.
    Perrine, George
    Mull, Stephanie
    Boehm, Kristi A.
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 155 - 161
  • [28] Development of Drugs Against Hormone-Refractory Prostate Cancer
    Kageyama, Yukio
    DRUG DEVELOPMENT RESEARCH, 2008, 69 (07) : 431 - 450
  • [29] Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results
    George, D. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    Zurita, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] TRIMETREXATE IN ADVANCED HORMONE-REFRACTORY PROSTATE-CANCER - AN ECOG PHASE-II TRIAL
    WITTE, RS
    YEAP, BY
    TRUMP, DL
    INVESTIGATIONAL NEW DRUGS, 1994, 12 (03) : 255 - 258
12345